Pfizer and BioNTech’s vaccine 95% effective, according to comprehensive clinical trial results

The vaccine developed by the Pfizer and BioNTech alliance is 95% safe and effective in preventing Covid-19, according to comprehensive results from their clinical trial. A level similar to that of Moderna.

Pfizer released data Wednesday, November 18 what CNN qualifies as“Surprisingly positive” : the American group has announced that its vaccine developed in alliance with BioNTech is 95% safe and effective in preventing Covid-19, without major side effects, according to full results of their clinical trial. This places the vaccine at the same rate of effectiveness as that developed by Moderna.

Last week, Pfizer and BioNTech released preliminary data suggesting the vaccine offered 90% protection against Covid-19 and said there was no safety issue, remind her BBC. But this time, lift the chain, Pfizer also claims that the vaccine is 94% effective in people over 65. Either the same efficiency for the elderly, “Who are most exposed to the virus and whose immune system is weaker”, than for the youngest.

The companies say they will now apply for permission to use their vaccine urgently in the United States in the coming days. If the vaccine was approved by the Food and Drug Administration (FDA, the American Medicines Agency), the first inoculations could take place in December in the country. In Europe, the director of the European Medicines Agency (EMA), Emer Cooke, stated that she “Hoped” that the agency would have an opinion on the authorization of a vaccine by the end of the year, report Politico Europe.

Accumulation of encouraging news

While many questions remain unanswered – it is not known whether these vaccines prevent infection with the coronavirus or if they only reduce the severity of the disease, it is not known for how long they protect … – these announcements are prompting the hope of the press. “The accumulation of positive data (…) suggests that life could return to normal if enough people are inoculated ”, advance with caution the Wall Street Journal.

“More good news about vaccines, that’s what we’ve all been waiting for”, rejoices the BBC. “But this vaccine is still far from being used on a large scale”, warns the British channel. In particular because of “The huge problem of availability”: “Pfizer promises 50 million doses by the end of the year. But remember: this is a two dose vaccine. ” Enough for 22.5 million people and a long way from global needs.

“The end of the pandemic is now within sight”, written The Atlantic.

The tasks ahead – making vaccines on a large scale, distributing them via a cold chain or even ultra cold [le vaccin de Pfizer/BioNTech doit être conservé à -70 degrés Celsius et celui de Moderna à -20 degrés Celsius], and persuading suspicious Americans to take them – are not trivial, but they are all within the realm of human knowledge. The most delicate moment has passed: Scientific uncertainty [quant à l’efficacité de] vaccines [contre le] Covid-19 is resolved. Vaccines work. And for that, we can breathe a collective sigh of relief. ”

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.